ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.
Company codeNDRA
Company nameENDRA Life Sciences Inc
IPO dateJun 28, 2017
Founded at2007
CEOMr. Alexander Y. Tokman
Number of employees21
Security typeOrdinary Share
Fiscal year-endJun 28
Address3600 Green Ct Ste 350
CityANN ARBOR
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code48105-2440
Phone17343350468
Websitehttps://www.endrainc.com/
Company codeNDRA
IPO dateJun 28, 2017
Founded at2007
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data